Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.82 |
| ▸ | PDE5A | O76074 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cartazolate SCHEMBL123839 | 0.90 | PDE4B (1.00) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL6289439 | 0.86 | PDE4B (0.73) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL987741 | 0.86 | PDE4B (0.60) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL2457683 | 0.85 | PDE4B (0.72) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL4811745 | 0.83 | PDE4B (0.69) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL9838278 | 0.81 | PDE4B (0.84) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL4820250 | 0.81 | PDE4B (0.73) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL582697 | 0.81 | PDE4B (0.92) | PDE4BPDE5AMAPTMEN1HPGD | |
| SCHEMBL4816464 | 0.81 | PDE4B (0.73) | PDE4BPDE5AMAPTMEN1HPGD | |
| Etazolate SCHEMBL16703320 | 0.81 | MEN1 (0.98) | PDE4BPDE5AMAPTMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2049556-B1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8173609-B2 | Macrolides useful against inflammatory and allergic diseases | BASILEA PHARMACEUTICA AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | BASILEA PHARMACEUTICA AG (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2049556-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | Basilea Pharmaceutica AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017696-A1 | NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES | BASILEA PHARMACEUTICA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120706-A1 | Macrolides Useful Against Inflammatory and Allergic Diseases | HRH4, HRH2, IL4 | PDE4B 2041/4885PDE5A 4135/4885MAPT 4860/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE4B 2412/4885PDE5A 3491/4885MAPT 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.